Trellus Management Company’s Biolase, Inc. BIOL Stock Holding History

Trellus Management Company’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7	Closed	-$9K	–	86
2019 Q4	$9K	Hold	7	–	–	0.02%	61
2019 Q3	$15K	Sell	7 -40	-85%	-$132K	0.02%	67
2019 Q2	$171K	Hold	47	–	–	0.23%	61
2019 Q1	$277K	Sell	47 -11	-19%	-$53.4K	0.53%	47
2018 Q4	$143K	Buy	58 +13	+29%	+$42K	0.32%	46
2018 Q3	$231K	Buy	+45	New	+$180K	0.33%	54
2018 Q2	–	Sell	-30	Closed	-$152K	–	76
2018 Q1	$152K	Sell	30 -16	-35%	-$89.8K	0.28%	61
2017 Q4	$246K	Buy	46 +16	+53%	+$113K	0.34%	58
2017 Q3	$226K	Buy	30 +2	+7%	+$17.2K	0.31%	67
2017 Q2	$340K	Buy	28 +5	+22%	+$74.2K	0.5%	52
2017 Q1	$394K	Buy	23 +17	+283%	+$308K	0.6%	48
2016 Q4	$106K	Buy	6 +1	+20%	+$19.8K	0.16%	64
2016 Q3	$112K	Hold	5	–	–	0.16%	64
2016 Q2	$71K	Hold	5	–	–	0.12%	58
2016 Q1	$79K	Hold	5	–	–	0.14%	60
2015 Q4	$51K	Buy	+5	New	+$54.6K	0.08%	79

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Trellus Management Company's BIOL Position: Q1 2020 in Review

Trellus Management Company sold out of Biolase, Inc. (BIOL) in Q1 2020, closing a stake of 7 shares — an estimated $9K sold.

Trellus Management Company first reported a position in BIOL in Q4 2015 and held it in 16 quarters. The position peaked at $394K in Q1 2017. 21 funds tracked by Wall St. Rank hold BIOL as of Q1 2020.

Trellus Management Company reported no remaining Biolase, Inc. position as of Q1 2020 after selling out during the quarter.
Trellus Management Company sold 7 Biolase, Inc. shares in Q1 2020, an estimated $9K.
Trellus Management Company first reported a position in Biolase, Inc. in Q4 2015 and held it in 16 quarters.
Trellus Management Company's Biolase, Inc. position peaked at $394K in Q1 2017.
21 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2020.

Based on Trellus Management Company's 13F filing for Q1 2020, filed 6 May 2020.